Publications

Homeless Children: Update on Research, Policy, Programs, and Opportunities. Section II. Research About Homeless Children

Beginning with the earliest published reports in 1987, the literature on homeless children now spans about 23 years. Viewing these studies in the aggregate, a set of “first generation” studies, many of which were reviewed 15 years ago by Rafferty and Shinn (1991), can be distinguished from a second stage of investigations published after the r

Screening for Domestic Violence in Health Care Settings. References

Agency for Healthcare Research and Quality. “Evaluation of the U.S. Preventive Services Task Force: Final Report.” December 2007. Accessed 3 March 2013 from http://www.ahrq.gov/research/findings/final-reports/uspstf/index.html#contents

Screening for Domestic Violence in Health Care Settings

In light of recent policy changes in support of domestic violence screening in health care settings, this policy brief presents the state of practice and research on this preventive service. The brief discusses reasons for screening in health care settings, the current prevalence of screening and reasons this prevalence is relatively low, existing

pb_screeningDomestic.pdf
PDF

CHIPRA Mandated Evaluation of Express Lane Eligibility: First Year Findings. References

Aizer, A. “Low Take-Up in Medicaid: Does Outreach Matter and for Whom?” AEA Papers and Proceedings, vol. 93 , no. 2, May 2003, pp. 238 –241. Bansak, C., and S. Raphael. “The Effects of State Policy Design Features on Take-Up and Crowd-Out Rates for the State Children’s Health Insurance Program.” Journal of Policy Analysis and Man

CHIPRA Mandated Evaluation of Express Lane Eligibility: First Year Findings. 2. Additional Data Sources

The multivariate analysis accounts for many variables, such as changes in economic conditions and in various non-ELE enrollment policies that might otherwise bias the estimates of ELE’s effects. To construct these variables, we draw on a number of data sources:

Strategies for Measuring the Quality of Psychotherapy: A White Paper to Inform Measure Development and Implementation. References

Aarons, G.A., C. Glisson, P.D. Green, K. Hoagwood, K.J. Kelleher, J.A. Landsverk, Research Network on Youth Mental Health, J.R. Weisz, B. Chorpita, R. Gibbons, C. Glisson, E.P. Green, K. Hoagwood, P.S. Jensen, K. Kelleher, J. Landsverk, S. Mayberg, J. Miranda, L. Palinkas, and S. Schoenwald. "The Organizational Social Context of Mental Health Serv

Strategies for Measuring the Quality of Psychotherapy: A White Paper to Inform Measure Development and Implementation

Various types of psychotherapy can benefit people who experience depression, anxiety, and other common mental disorders. However, the extent to which these psychotherapies are available and delivered effectively is largely unknown. In the context of health care reforms that encourage performance measurement, a strong set of measures focused on psy

QualPsy.pdf
PDF

Examination of Clinical Trial Costs and Barriers for Drug Development. 6 References

Adams, C., & Brantner, V. (2006). Estimating The Cost Of New Drug Development: Is It Really $802 Million? Health Affairs, 25 (2). Adams, C., & Brantner, V. (2010). Spending on new drug development. Health Economics , 19(2), 130- 141. Angell, M. (2004). Introduction: Drugs are Different. In M. Angell, The Truth About the Drug Comp

Survey Data on Health Insurance Coverage for 2013 and 2014. Appendix 2: Cps-asec: Sources of Health Insurance Coverage in 2013

The estimates shown in Table A-2 are based on the percentage of people for whom each source of coverage was reported in the CPE-ASEC for CY 2013. These percentages sum to more than 100 percent because some people report multiple forms of coverage.

Survey Data on Health Insurance Coverage for 2013 and 2014. Conclusion: Looking AHEAD to the Present

Gallup-Healthways WBI health insurance survey data provide the most up-to-date data on insurance coverage so far in 2014. An analysis of these data published by the New England Journal of Medicine shows that 10.3 million adults had gained coverage through June 2014. 27

Survey Data on Health Insurance Coverage for 2013 and 2014. 2013: Current Population Survey Annual Social and Economic Supplement (CPS-ASEC) and American Community Survey (ACS)

The CPS-ASEC and ACS estimates released on September 16, 2014 cover CY 2013. 20 These data thus provide a baseline for future analyses of changes in health insurance coverage under the Affordable Care Act.

Survey Data on Health Insurance Coverage for 2013 and 2014. Mid-2014: Gallup-Healthways Well-Being Index (WBI)

Analysis of data from the Gallup-Healthways WBI by Sommers et al. shows a decline of 26 percent in the uninsured rate for nonelderly adults. The study estimated a 5.2 percentage point reduction in the uninsured rate for 18 to 64 year olds in the second quarter of 2014, compared to the base period from the first quarter of 2012 through the third qu

Variation and Trends in Medigap Premiums. Appendix A: Medicare Benefits for Parts A and B and Cost Sharing Requirements, 2011

PART A Deductible $1,132 per benefit period Inpatient hospital Days 1-60 Days 61-90 Days 91-150 After 150 Days No coinsurance $283per day $566 per day (for up to 60 lifetime reserve days) Not covered

Variation and Trends in Medigap Premiums. Background

While Medicare covers many services, it does not cover them in full. Individuals with Medicare coverage are responsible for some out‐of‐pocket expenses such as copayments, coinsurance, and deductibles (see Appendix A for more information). Fee‐for‐service Medicare also does not include a cap on out‐of‐pocket payments. Medigap (also cal

Examination of Clinical Trial Costs and Barriers for Drug Development. 2.1.1 Publically Available Literature

Although the literature on the early stages of the pharmaceutical decision-making process is not extensive, there is some research that has characterized the process. We used this information to help define the components of the model. Some examples are the work performed at the Massachusetts Institute of Technology (MIT) Center for Biomedical Inn

Rapid Evaluation Approaches for Complex Initiatives. Bibliography

Argyris, C. Reasoning, Learning, and Action: Individual and Organizational . San Francisco: Jossey-Bass, 1982. AHRQ. (Agency for Healthcare Research and Quality). National Quality Measures Clearinghouse. “Uses of Quality Measures.” Available at [ http://www.qualitymeasures.ahrq.gov/tutorial/using.aspx ]. Accessed September 20, 2013.

Analytical Framework for Examining the Value of Antibacterial Products. 7 References

About NIAID . (2012, February 29). Retrieved November 12, 2012, from National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/about/pages/default.aspx Aldy, J. E., & Viscusi, W. K. (2008). Adjusting the Value of a Statistical Life for Age and Cohort Effects. The Review of Economics and Statistics, 90 (3), 573–581

Analytical Framework for Examining the Value of Antibacterial Products. 1.3 Data Sources

For constructing our EPV model, we compiled information from a variety of sources, including:

Identifying and Serving LGBTQ Youth: Case Studies of Runaway and Homeless Youth Program Grantees. References

Acevedo-Polakovich, I., B. Bell, P. Gamache, and A.S. Christian. “Service Accessibility for Lesbian, Gay, Bisexual, Transgender, and Questioning Youth.” Youth & Society, vol. 45, 2011, pp. 75–97. American Psychological Association. “Guidelines for Practice with Lesbian, Gay, and Bisexual Clients.” Washington, DC: APA, 2011.

Identifying and Serving LGBTQ Youth: Case Studies of Runaway and Homeless Youth Program Grantees. A. Organizational Strategies

We explored agencies’ implementation of six main organizational strategies for serving LGBTQ RHY, focusing on recommendations frequently made in publications addressing service provision to these populations: (1) adopting policies prohibiting discrimination and harassment, (2) protecting the confidentiality of information about youth, (3) establ

Content by Keyword: Publications